Gilead Sciences, Inc. stock price

Gilead Sciences, Inc. latest news:


  • 02/17/2018 10:18:22

    UPDATE 1-Gilead wins reversal of $2.54 bln hepatitis C drug patent verdict

    Feb 17 (Reuters) - A federal judge in Delaware has overturned a jury's verdict requiring Gilead Sciences Inc to pay a record $2.54 billion because its hepatitis C drugs Sovaldi and Harvoni infringed a patent held by rival Merck & Co Inc.

  • 02/08/2018 00:17:33

    BRIEF-GSK's ViiV Healthcare Says Filed Patent Infringement Litigation Against Gilead Sciences

    Glaxosmithkline Plc(GSK): * VIIV FILES PATENT INFRINGEMENT LITIGATION. * Glaxosmithkline Plc(GSK) - VIIV ‍ANNOUNCED IT FILED PATENT INFRINGEMENT LITIGATION AGAINST GILEAD SCIENCES INC. OVER BICTEGRAVIR IN UNITED STATES AND CANADA​ Source text for Eikon: Further company coverage:

  • 02/07/2018 19:17:09

    UPDATE 4-U.S. FDA approves Gilead triple HIV drug, rival files lawsuit

    Feb 7 (Reuters) - The U.S. Food and Drug Administration on Wednesday approved Biktarvy, Gilead Sciences Inc's once-daily, triple-combination tablet for treatment of HIV infection, paving the way for the biotech company to capture more of the multibillion-dollar HIV drug market.

  • 02/07/2018 15:28:41

    U.S. FDA approves Gilead triple HIV drug, rival files lawsuit

    The U.S. Food and Drug Administration on Wednesday approved Biktarvy, Gilead Sciences Inc's (GILD) once-daily triple-combination tablet for treatment of HIV infection, paving the way for the biotech company to capture more of the multibillion-dollar HIV drug market.

  • 02/07/2018 14:46:20

    BRIEF-ViiV Healthcare files patent infringement litigation against Gilead Sciences

    * VIIV HEALTHCARE FILES PATENT INFRINGEMENT LITIGATION AGAINST GILEAD SCIENCES INC. OVER BICTEGRAVIR. * VIIV HEALTHCARE - FILED PATENT INFRINGEMENT LITIGATION AGAINST GILEAD SCIENCES INC. OVER BICTEGRAVIR IN THE UNITED STATES AND CANADA. * VIIV HEALTHCARE - WILL SEEK TO PROVE THAT GILEAD'S TRIPLE COMBINATION HIV DRUG INFRINGES CO'S PATENT COVERING DOLUTEGRAVIR AND MANY OTHER COMPOUNDS.

  • 02/07/2018 13:05:02

    U.S. FDA approves Gilead's three-drug HIV regimen

    The U.S. Food and Drug Administration on Wednesday approved Gilead Sciences Inc's (GILD) three-drug regimen to treat HIV-1 infection. The treatment, Biktarvy, is a once-daily tablet that combines three previously approved drugs - bictegravir, emtricitabine and tenofovir alafenamide, the company said. It is available to patients who have been on a stable regimen for at least three months.

  • 02/06/2018 15:50:53

    Gilead 4th-qtr hepatitis C drug sales plummet, sees further slowdown

    Gilead Sciences Inc(GILD) on Tuesday said fourth-quarter sales of its flagship hepatitis C drugs fell by more than half amid increased competition, and the company forecast a further slowdown for the current year. Gilead's shares fell slightly after the closing bell.

  • 02/06/2018 15:50:28

    UPDATE 1-Gilead 4th-qtr hepatitis C drug sales plummet, sees further slowdown

    Feb 6 (Reuters) - Gilead Sciences Inc on Tuesday said fourth-quarter sales of its flagship hepatitis C drugs fell by more than half amid increased competition, and the company forecast a further slowdown for the current year.

  • 02/06/2018 15:42:48

    Gilead Q4 hepatitis C drug sales plummet, shrs drop 3 pct after hours

    By Deena Beasley. Gilead Sciences Inc (GILD) on Tuesday said fourth-quarter sales of its flagship hepatitis C drugs fell by more than half amid increased competition and forecast a further slowdown in the current year, sending its shares lower after the closing bell. For full-year 2018, the biotechnology company forecast product sales of $20 billion to $21 billion, down from $25.7 billion last year.

  • 02/06/2018 15:42:26

    CORRECTED-Gilead Q4 hepatitis C drug sales plummet, shrs drop 3 pct after hours

    Feb 6 (Reuters) - Gilead Sciences Inc on Tuesday said fourth-quarter sales of its flagship hepatitis C drugs fell by more than half amid increased competition and forecast a further slowdown in the current year, sending its shares lower after the closing bell.

  • 02/06/2018 14:25:46

    Gilead shares slide as outlook falls short

    Gilead Sciences Inc. shares declined in the extended session Tuesday after the drugmaker topped Wall Street estimates for the quarter but offered an outlook that fell short of the consensus. Gilead shares fell 2.4% to $78.48 after hours, following a 2.6% gain in the regular session. The company reported a fourth-quarter loss of $3.87 billion, or $2.96 a share, compared with net income of $3.11 billion, or $2.34 a share, in the year-ago period. Adjusted earnings, which factored out a $5.5 billion charge from the recently passed U.S. tax overhaul, were $1.78 a share. Revenue fell to $5.95 billion from $7.32 billion in the year-ago period. Analysts surveyed by FactSet had estimated $1.67 a share on revenue of $5.71 billion. For the year, Gilead estimates revenue of $20 billion to $21 billion. Analysts expect revenue of $21.94 billion. Separately, Gilead said its board approved a 10% hike in the quarterly dividend to 57 cents a share.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 01/17/2018 16:40:10

    Florida man gets prison for trading on tip about Gilead deal

    Jan 17 (Reuters) - A Florida man was sentenced on Wednesday to one year in prison for engaging in insider trading based on a tip he received from an ex-Morgan Stanley broker about Gilead Sciences Inc's planned $11.2 billion purchase of Pharmasset Inc in 2011, prosecutors said.

  • More trends:

    Glacier Bancorp, Inc.GBCI | Gladstone Capital CorporationGLAD | Gladstone Capital CorporationGLADO | Gladstone Commercial CorporationGOOD | Gladstone Commercial CorporationGOODN | Gladstone Commercial CorporationGOODO | Gladstone Commercial CorporationGOODP | Gladstone Investment CorporationGAIN | Gladstone Investment CorporationGAINN | Gladstone Investment CorporationGAINO |